Microvessel density and VEGF, HIF-1α expression in primary oral melanoma: Correlation with prognosis

Oral Diseases

Volumn 19, Issue 6, 2013, Pages 620-627

  Simonetti, O ^a   Lucarini, G ^a   Rubini, C ^a   Goteri, G ^a   Zizzi, A ^a   Staibano, S ^b   Campanati, A ^a   Ganzetti, G ^a   Di Primio, R ^a   Offidani, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

HIF 1 ; Invasive margin; MVD; Oral melanoma; Survival; VEGF

Indexed keywords

CD34 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CAPILLARY DENSITY; CELL INFILTRATION; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTE; MELANOMA; MOUTH CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

HIF-1Α; INVASIVE MARGIN; MVD; ORAL MELANOMA; SURVIVAL; VEGF;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; ANTIGENS, CD34; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTES; MELANOMA; MICROVESSELS; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PALATAL NEOPLASMS; PROGNOSIS; SEX FACTORS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880312315     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12048     Document Type: Article

References (47)

1. Batmunkh E, Shimada M, Morine Y et al (2010). Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma. Int J Clin Oncol 15: 59-64.
2. Boring CC, Squires TS, Tong T, Montgomery S (1994). Cancer statistics. CA Cancer J Clin 44: 7-26.
3. Chen D, Li M, Luo J, Gu W (2003). Direct interactions between HIF-1 alpha and mdm2 modulate P53 function. J Biol Chem 278: 13595-13598.
4. Chen WT, Huang CJ, Wu MT, Yang SF, Su YC, Chai CY (2005). Hypoxia-induclible factor-1 alpha is associated with risk of aggressive behaviour and tumor angiogenesis in gastrointestinal stromal tumor. Jpn J Clin Oncol 35: 207-213.
5. Cianchi F, Cuzzocrea S, Vinci MC et al (2010). Heterogeneous expression of cyclooxigenase-2 and inducible nitric oxide synthase within colorectal tumors: correlation with tumor angiogenesis. Dig Liver Dis 42: 20-27.
6. Deniz H, Karakök M, Yagci F, Güldür ME (2010). Evaluation of relationship between HIF-1alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas. Int Urol Nephrol 42: 103-107.
7. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995). Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039.
8. Femiano F, Lanza A, Buonaiuto C, Gombos F, Di Spirito F, Cirillo N (2008). Oral malignant melanoma: a review of the literature. J Oral Pathol Med 37: 383-388.
9. Ferrara N, Houck K, Jakeman L, Leung DW (1992). Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinol Rev 13: 18-32.
10. Fina L, Molgaard H, Robertson D et al (1990). Expression of the CD34 gene in vascular endothelial cells. Blood 75: 2417-2426.
11. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
12. Folkman J (1995). Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763.
13. Forsythe JA, Jjang B-H, Iyer NV et al (1996). Activation of vascular endothelial growth factor gene trascription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613.
14. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL (1995). Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 177: 275-283.
15. Freedberg IM, Eisen AZ, Wolff K (1999). In: Goldsmith LA, Katz SI, Fitzpatrick TB, eds. Dermatology in General Medicine, 5th edn. McGraw-Hill: New York, pp. 133-143.
16. Giatromanolaki A, Siuridis E, Koukourakis MI (2004). Tumour angiogenesis: vascular growth and survival. APMIS 122: 431-440.
17. Hashemi Pour MS (2008). Malignant melanoma of the oral cavity: a review of the literature. Indian J Dental Res 19: 47-51.
18. Hicks MJ, Flaitz CM (2000). Oral mucosal melanoma: epidemiology and pathobiology. Oral Oncol 36: 152-169.
19. Khare VK, Albino AP, Reed JA (1998). The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions. J Cutan Pathol 25: 2-10.
20. Laurenco SV, Sangüeza AM, Sotto MN et al (2009). Primary oral mucosa melanoma: a series of 35 new cases from South America. Am J Dermatopathol 31: 323-330.
21. Lever WF, Schaumburg-Lever G (1990). Histopathology of the Skin, 7th edn. J.B. Lippincott: Philadelphia, pp. 756-805.
22. Lucarini G, Zizzi A, Belvederesi L, Kyriakidou K, Mazzucchelli R, Biagini G (2007). Increased VEGF165 expression in HCT116 colon cancer cells after transient transfection with a GFP vector encoding HIF-1 gene. J Exp Clin Cancer Res 26: 515-519.
23. Mehnert JM, McCarthy MM, Jilaveanu L et al (2010). Quantitative Expression of VEGF, VEGF-R1, VEGF-R2 and VEGFR3 in Melanoma Tissue Microarrays. Hum Pathol 41: 375-384.
24. Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Villaret DB, Mendenhall NP (2005). Head and neck mucosal melanoma. Am J Clin Oncol 28: 626-630.
25. Minardi D, Lucarini G, Filosa A et al (2008). Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1 alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Int J Immunopathol Pharmacol 21: 447-455.
26. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999). Vascular endothelial growth factor (VEGF) and its receptor. FASEB J 13: 9-22.
27. Nielsen JS, McNagny KM (2008). Novel functions of the CD34 family. J Cell Sci 121: 3683-3689.
28. O'Rourke JF, Dachs GU, Gleadle JM et al (1997). Hypoxia response elements. Oncol Res 9: 327-332.
29. Patrick RJ, Fenske NA, Messina JL (2007). Primary mucosal melanoma. J Am Acad Dermatol 56: 828-834.
30. Paweletz N, Kneirim M (1989). Tumour related angiogenesis. Crit Rev Oncol Haematol 9: 197-242.
31. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ (2005). Diabetic retinopathy is associated with a switch in splicing from anti-to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 48: 2422-2427.
32. Prasad ML, Patel SG, Huvos AG, Shah JP, Busam KJ (2004). Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors. Cancer 100: 1657-1664.
33. Pratheeshkumar P, Kuttan G (2011). Vernolide-A inhibits radiation-induced hypoxia-medisted tumor angiogenesis by regulating HIF-1α, MMP-2, MMP-9 and VEGF. J Environ Pathol Toxicol Oncol 30: 139-151.
34. Rajaganeshan R, Prasad R, Guillou PJ, Scott N, Poston G, Jayne DG (2009). Expression patterns of hypoxic markers at the invasive margin of colorectal cancers and liver metastases. Eur J Surg Oncol 35: 1286-1294.
35. Reed JA, McNutt NS, Albino AP (1994). Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization: Implications for tumor progress. Am J Pathol 144: 329-336.
36. Ribatti D, Ennas MG, Vacca A et al (2003). Tumor vascularity and tryptase-positive mast cell correlate with a poor prognosis in melanoma. Eur J Clin Invest 33: 420-425.
37. Seetharamu N, Ott PA, Pavlick AC (2010). Mucosal melanomas: a case-based review of the literature. Oncologist 15: 772-781.
38. Shalaby F, Rossant J, Yamaguchi TP et al (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66.
39. Shibaji T, Nagao M, Ikeda N et al (2003). Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res 23: 4721-4727.
40. Shweiki D, Neeman M, Itin A, Keshet E (1995). Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 92: 768-772.
41. Simonetti O, Lucarini G, Brancorsini D et al (2002). Immunohistochemical Expression of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 2, and Matrix Metalloproteinase 9 in Cutaneous Melanocytic Lesions. Cancer 95: 1963-1970.
42. Sortino Rachou AM, De CamargoCancela M, Voti L, Curado MP (2009). Primary oral melanoma: population based incidence. Oral Oncol 45: 254-258.
43. Symvoulakis EK, Kyrmizakis DE, Drivas EI, Koutsopoulos AV et al (2006). Oral mucosal melanoma: a malignant trap. Head Face Med 28: 2-7.
44. Tomicic J, Wanebo HJ (2003). Mucosal melanomas. Surg Clin North Am 83: 237-252.
45. Ushijima C, Tsukamoto S, Yamazaki K, Yoshino I, Sugio K, Sugimachi K (2001). High vascularity in the peripheral region of non small cell lung cancer tissue is associated with tumor progression. Lung Cancer 34: 233-241.
46. Uzzan B, Nicolas P, Cucherat M, Perret GY (2004). Microvessel density as a prognostic factor in woman with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64: 2941-2955.
47. Zhong H, De Marzo AM, Laughner E et al (1999). Overexpression of Hypoxia-inducible Factor 1 in Common Human Cancers and Their Metastases. Cancer Res 59: 5830-5835.